Etiopathogenetic grounding of the treatment of voice-speech professions with functional dysphonia on the background of subclinical psycho-emotional disorders during the COVID-2019 pandemic

Q4 Medicine

Otorhinolaryngology Clinics Pub Date : 2022-07-29 DOI:10.37219/2528-8253-2022-3-57

I. Sinaiko, Vasyl I. Troyan, Veronica M. Kryshtal

{"title":"Etiopathogenetic grounding of the treatment of voice-speech professions with functional dysphonia on the background of subclinical psycho-emotional disorders during the COVID-2019 pandemic","authors":"I. Sinaiko, Vasyl I. Troyan, Veronica M. Kryshtal","doi":"10.37219/2528-8253-2022-3-57","DOIUrl":null,"url":null,"abstract":"The aim of the research: Improvement of the traditional complex treatment of voice-speaking professions during the COVID-2019 pandemic with functional dysphonia on the background of subclinical psycho-emotional disorders by appointment neurotransmitter drugs.\nMaterials and methods: The study involved 49 people of voice-speech professions with functional disorders of the voice function of the hypotonic type, who were diagnosed with subclinical disorders of the psychoemotional state by questioning on the hospital anxiety and depression scale (HADS). Before and after treatment, voice disorders were diagnosed using perceptual evaluation of the GRBAS voice scale and video stroboscopy of the larynx. The impact of voice disorders on quality of life during the pandemic was assessed using the Voice COVID-19 (VC-19) questionnaire.\nAll patients received standardized treatment, which consisted of the use of metabolic, stimulant drugs, physiotherapy and instillation of drugs into the larynx. In 26 patients of the main group (MG), in addition to treatment, a neurotransmitterotropic drug (\"Beresh Magnesium plus B6\") was prescribed. The comparison group (CG) consisted of 23 people who received traditional therapy. Descriptive statistics were used for statistical analysis of the effectiveness of treatment, comparison of the difference in quantitative indicators by the method of nonparametric statistics using the Mann-Whitney-U-test.\nResults: The use of the neurotransmitter correction agent \"Beresh Magnesium plus B6\" by the patients with MG contributed to the suppression of their susceptibility to anxiety, stress and, as a result of these processes, made it possible to obtain, in comparison with the control group, a significant improvement in such indicators of acoustic parameters as voice strength by 5.78%, integral stroboscopy index - 13.34% and improvement of the quality of life by 34.03%, which indicates the effectiveness of the use of magnesium compounds with vitamin B6 in the complex treatment of patients with hypotonic dysphonia against the background of subclinical psychoemotional disorders.\nConclusions: Addit ional appointment of magnesium citrate and magnesium oxide compounds with vitamin B6, which has a modulating effect on neurotransmitters that affect depression and anxiety, to basic therapy for patients of main group, made it possible to obtain a significant improvement in the main perceptual and functional indicators of the voice and quality of life.","PeriodicalId":38742,"journal":{"name":"Otorhinolaryngology Clinics","volume":"22 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Otorhinolaryngology Clinics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37219/2528-8253-2022-3-57","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The aim of the research: Improvement of the traditional complex treatment of voice-speaking professions during the COVID-2019 pandemic with functional dysphonia on the background of subclinical psycho-emotional disorders by appointment neurotransmitter drugs. Materials and methods: The study involved 49 people of voice-speech professions with functional disorders of the voice function of the hypotonic type, who were diagnosed with subclinical disorders of the psychoemotional state by questioning on the hospital anxiety and depression scale (HADS). Before and after treatment, voice disorders were diagnosed using perceptual evaluation of the GRBAS voice scale and video stroboscopy of the larynx. The impact of voice disorders on quality of life during the pandemic was assessed using the Voice COVID-19 (VC-19) questionnaire. All patients received standardized treatment, which consisted of the use of metabolic, stimulant drugs, physiotherapy and instillation of drugs into the larynx. In 26 patients of the main group (MG), in addition to treatment, a neurotransmitterotropic drug ("Beresh Magnesium plus B6") was prescribed. The comparison group (CG) consisted of 23 people who received traditional therapy. Descriptive statistics were used for statistical analysis of the effectiveness of treatment, comparison of the difference in quantitative indicators by the method of nonparametric statistics using the Mann-Whitney-U-test. Results: The use of the neurotransmitter correction agent "Beresh Magnesium plus B6" by the patients with MG contributed to the suppression of their susceptibility to anxiety, stress and, as a result of these processes, made it possible to obtain, in comparison with the control group, a significant improvement in such indicators of acoustic parameters as voice strength by 5.78%, integral stroboscopy index - 13.34% and improvement of the quality of life by 34.03%, which indicates the effectiveness of the use of magnesium compounds with vitamin B6 in the complex treatment of patients with hypotonic dysphonia against the background of subclinical psychoemotional disorders. Conclusions: Addit ional appointment of magnesium citrate and magnesium oxide compounds with vitamin B6, which has a modulating effect on neurotransmitters that affect depression and anxiety, to basic therapy for patients of main group, made it possible to obtain a significant improvement in the main perceptual and functional indicators of the voice and quality of life.

查看原文本刊更多论文

2019冠状病毒病大流行期间以亚临床心理情绪障碍为背景的语音职业功能性语音障碍治疗的发病基础

研究目的:改进以亚临床心理情绪障碍为背景的新型冠状病毒大流行期间语音行业功能性语音障碍的传统综合治疗方法。材料与方法:采用医院焦虑抑郁量表(HADS)对49例低张力型语音功能障碍的语音语音专业人士进行心理情绪状态亚临床障碍的问询。在治疗前后，使用GRBAS语音量表的感知评价和喉部视频频闪检查诊断语音障碍。使用voice COVID-19 (VC-19)问卷评估了大流行期间语音障碍对生活质量的影响。所有患者均接受标准化治疗，包括使用代谢药物、兴奋剂、物理治疗和喉部滴注药物。在主组(MG) 26例患者中，除治疗外，还开了一种神经递质药物(“Beresh镁+ B6”)。对照组(CG) 23例接受传统治疗。采用描述性统计方法对治疗效果进行统计分析，定量指标的差异比较采用非参数统计方法，采用mann - whitney - u检验。结果:MG患者使用神经递质矫正剂“Beresh镁+ B6”有助于抑制其对焦虑、压力的易感性，因此，与对照组相比，声音强度等声学参数指标显着提高5.78%，积分频闪指数提高13.34%，生活质量提高34.03%。这表明镁化合物与维生素B6在亚临床心理情绪障碍背景下低张力发声障碍患者的综合治疗中的有效性。结论:主组患者在基础治疗基础上加用柠檬酸镁和氧化镁复合物(含维生素B6)对影响抑郁和焦虑的神经递质具有调节作用，可显著改善语音和生活质量等主要感知和功能指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Otorhinolaryngology Clinics Medicine-Otorhinolaryngology

CiteScore

0.10

自引率

0.00%

发文量

期刊介绍： Otorhinolaryngology Clinics: An International Journal is an International periodical devoted at exploring connections between clinical experience and world literature, and understanding of various pathologies and diseases related to the ear, nose and throat. Issues of recent advancements and research related to disease, illness, health and medical science are examined through various evidence-based clinical research studies. This journal proposes to serve as a collection of clinical notes, with an international perspective, along with the recent advances for postgraduates and consultants. The readership for this journal would include a wide variety of healthcare professionals, such as otolaryngologists, head and neck surgeons, ENT nurses as well as scholars and academicians in the field of medicine, trauma, surgery, etc. This journal aims to encourage the analysis of clinical data from various centers all over the world using standardized protocols to develop an international consensual perspective on the management of disorders related to the field of otorhinolaryngology. Recently, we have introduced "Case Reports", "How I Do It" and "Original Research" categories in the process of expanding the scope of the journal. Thisis a peer-reviewed journal of which three issues would be published each year. Each future issue will cover a different topic of special interest in the field of otorhinolaryngology and head and neck surgery. This issue is the first of its kind dedicated to "anesthesia in otorhinolaryngology" and contains a compilation of articles by experienced anesthesiologists dealing with a large volume of ENT and related surgeries. In each issue, the editors give their perspective based on the submitted articles. All non invited articles are peer-reviewed. Peer-revieweing helps in providing unbiased, independent, critical assessment of the results of the research study in question including the scientific process.